If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Hyōjun (標準): standard grade, contains more than 1.2% total nitrogen Jōkyū (上級): upper grade, contains more than 1.35% of total nitrogen Tokkyū (特級): special grade, contains more than 1.5% of total nitrogen
On October 17, faced with the PAVN's demonstrated ability to fight a conventional battle, the French command decided to abandon Lạng Sơn before it could come under attack, leaving behind considerable amounts of military supplies. The Viet-Minh now controlled most of the northern half of Tonkin.
=== Binding site === Advances in the field of recombinant protein engineering and expression, protein purification, NMR, X-ray crystallography and computational chemistry have improved the skills of drug designers to use data that have been gathered on the three-dimensional structures of protein ligand complexes. Most bacterial species have various types of PBP which differ in various ways such as enzymatic function, molecular weight and the affinity for β-lactam antibiotics. There are two types of enzymes that are particularly interesting with regard to the binding site of β-lactams: PBP and β-lactamases. Target alterations in the binding site of PBP have led to high-level resistance of β-lactams among bacteria like staphylococci, enterococci and pneumococci. For example, the binding site of PBP2 in Neisseria gonorrhoeae has been structurally determined and has three sequence motifs that can be seen in nearly all β-lactam interacting enzymes:
Sources: en.wikipedia.org
== Prognosis == Patient response to treatment will vary based on age, health, and the tolerance to medications and therapies. Metastasis occurs in about 39% of patients, most commonly to the lung. Features associated with poor prognosis include a large primary tumor (over 5 cm across), high grade disease, co-existent neurofibromatosis, and the presence of metastases. It is a rare tumor type, with a relatively poor prognosis in children. In addition, MPNSTs are extremely threatening in NF1. In a 10-year institutional review for the treatment of chemotherapy for MPNST in NF1, which followed the cases of 1 per 2,500 in 3,300 live births, chemotherapy did not seem to reduce mortality, and its effectiveness should be questioned. Although with recent approaches with the molecular biology of MPNSTs, new therapies and prognostic factors are being examined.
== Regulation of expression and activity == The formation of guanidinoacetate is normally the rate-limiting step of creatine biosynthesis. Consequently, the AGAT reaction is the most likely control step in the pathway, a hypothesis that is supported by a great deal of experimental work. Most important in this respect is the feedback repression of AGAT by creatine, the end-product of the pathway. Cyclocreatine, N-acetimidoylsarcosine, and N-ethylguanidinoacetate display repressor activity like creatine as well. L-Arginine and guanidinoacetate have only "apparent" repressor activity. They exert no effect on AGAT expression by themselves but are readily converted to creatine, which then acts as the true repressor. It has been suggested that AGAT activity in tissues is regulated in a number of ways including induction by growth hormone and thyroxine, inhibition of the enzyme by ornithine, and repression of its synthesis by creatine. Sex hormones may regulate the activity of AGAT. Treatment of male rats with testosterone propionate increases AGAT activity. In contrast, estrogen treatment decreases AGAT activity and induces weight loss. It is currently unclear whether the changes in the level of AGAT transcript results from altered mRNA stability or enhanced transcriptional rate. If estrogen-mediated alteration results from transcriptional regulation, the site of estrogen action is yet to be determined. GATM expression within the mouse placenta has been shown to be imprinted meaning only the maternal copy of GATM is expressed .
==== C4 ==== C4 plants capture carbon dioxide in their mesophyll cells (using an enzyme called phosphoenolpyruvate carboxylase which catalyzes the combination of carbon dioxide with a compound called phosphoenolpyruvate (PEP)), forming oxaloacetate. This oxaloacetate is then converted to malate and is transported into the bundle sheath cells (site of carbon dioxide fixation by RuBisCO) where oxygen concentration is low to avoid photorespiration. Here, carbon dioxide is removed from the malate and combined with RuBP by RuBisCO in the usual way, and the Calvin cycle proceeds as normal. The CO2 concentrations in the Bundle Sheath are approximately 10–20 fold higher than the concentration in the mesophyll cells. This ability to avoid photorespiration makes these plants more hardy than other plants in dry and hot environments, wherein stomata are closed and internal carbon dioxide levels are low. Under these conditions, photorespiration does occur in C4 plants, but at a much lower level compared with C3 plants in the same conditions. C4 plants include sugar cane, corn (maize), and sorghum.
Research is underway to use nanomaterials for purposes including more efficient solar cells, practical fuel cells, and environmentally friendly batteries. The most advanced nanotechnology projects related to energy are: storage, conversion, manufacturing improvements by reducing materials and process rates, energy saving (by better thermal insulation for example), and enhanced renewable energy sources. One major project that is being worked on is the development of nanotechnology in solar cells. Solar cells are more efficient as they get tinier and solar energy is a renewable resource. The price per watt of solar energy is lower than one dollar. Research is ongoing to use nanowires and other nanostructured materials with the hope of to create cheaper and more efficient solar cells than are possible with conventional planar silicon solar cells. Another example is the use of fuel cells powered by hydrogen, potentially using a catalyst consisting of carbon supported noble metal particles with diameters of 1–5 nm. Materials with small nanosized pores may be suitable for hydrogen storage. Nanotechnology may also find applications in batteries, where the use of nanomaterials may enable batteries with higher energy content or supercapacitors with a higher rate of recharging. Nanotechnology is already used to provide improved performance coatings for photovoltaic (PV) and solar thermal panels. Hydrophobic and self-cleaning properties combine to create more efficient solar panels, especially during inclement weather.
Sources: en.wikipedia.org
Furthermore, the rate of plutonium elimination in the excreta differed between species of animals by as much as a factor of five. Such variation made it extremely difficult to estimate what the rate would be for human beings.
== Function == This gene encodes adenylate cyclase-activating polypeptide 1. Mediated by adenylate cyclase-activating polypeptide 1 receptors, this polypeptide stimulates adenylate cyclase and subsequently increases the cAMP level in target cells. Adenylate cyclase-activating polypeptide 1 is not only a hypophysiotropic hormone (i.e. a substance that induces activity in the hypophysis), but also functions as a neurotransmitter and neuromodulator. In addition, it plays a role in paracrine and autocrine regulation of certain types of cells. This gene has five exons. Exons 1 and 2 encode the 5' UTR and signal peptide, respectively; exon 4 encodes an adenylate cyclase-activating polypeptide 1-related peptide; and exon 5 encodes the mature peptide and 3' UTR. This gene encodes three different mature peptides, including two isotypes: a shorter form and a longer form. A version of this gene has been associated with post-traumatic stress disorder (PTSD) in women (but not men). This disorder involves a maladaptive psychological response to traumatic, i.e. existence-threatening, events. Ressler et al. identified an association of a SNP in the gene coding for pituitary adenylate cyclase-activating polypeptide (PACAP), implicating this peptide and its receptor (PAC1) in PTSD. In mouse model of heavy alcohol drinking, PACAP seems to mediate alcohol effects on bed nucleus of the stria terminalis.
== Administrative divisions == The island of Negros is composed of 2 provinces, 1 highly urbanized city, 19 component cities, 38 municipalities and 1,219 barangays. Prior to the re-establishment of the Negros Island Region, Negros Occidental was designated as part of Western Visayas and Negros Oriental was designated as part of Central Visayas.
Tanzi, RE; Petrukhin, K; Chernov, I; Pellequer, JL; Wasco, W; Ross, B; Romano, DM; Brzustowicz, LM; Devoto, M; Peppercorn, J; Bush, AI; Sternlieb, I; Pirastu, M; Gusella, JF; Evgrafov, O; Penchaszadeh, GK; Honig, B; Edelman, IS; Soares, MB; Scheinberg, IH; Gilliam, TC (1993). "Identification of the Wilson's disease gene: A copper transporting ATPase with homology to the Menke's disease gene". Nature Genetics. 5 (4): 344–350. Bibcode:1993NaGen...5..344T. doi:10.1038/ng1293-344. PMID 8298641. S2CID 610188. Levy-Lahad, E; Wasco, W; Poorkaj, P; Romano, DM; Oshima Jm, Pettingell WH; Yu, C; Jondro, PD; Schmidt, SD; Wang, K; Crowley, AC; Fu, Y-H; Guenette, SY; Galas, D; Nemens, E; Wijsman, EM; Bird, TD; Schellenberg, GD; Tanzi, RE (1995). "Candidate gene for the chromosome 1 familial Alzheimer's disease locus". Science. 269 (5226): 973–977. Bibcode:1995Sci...269..973L. doi:10.1126/science.7638622. PMID 7638622. S2CID 27296868. Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, M; Go, R; Vekrellis, K; Selkoe, D; Saunders, A; Tanzi, RE (2000). "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q". Science. 290 (5500): 2302–2303. Bibcode:2000Sci...290.2302B. doi:10.1126/science.290.5500.2302. PMID 11125142. Bertram, L; Hiltunen, M; Parkinson, M; Ingelsson, M; Lange, C; Ramasamy, K; Mullin, K; Menon, R; Sampson, AJ; Hsiao, MY; Elliott, KJ; Moscarillo, T; Hyman, BT; Wagner, SL; Becker, KD; Blacker, D; Tanzi, RE (2005). "Family-based association between Alzheimer's disease and variants in UBQLN1". N. Engl. J. Med. 352 (9): 884–894.
Amyloids are aggregates of proteins characterised by a fibrillar morphology of typically 7–13 nm in diameter, a β-sheet secondary structure (known as cross-β) and ability to be stained by particular dyes, such as Congo red. In the human body, amyloids have been linked to the development of various diseases. Pathogenic amyloids form when previously healthy proteins lose their normal structure and physiological functions (misfolding) and form fibrous deposits within and around cells. These protein misfolding and deposition processes disrupt the healthy function of tissues and organs. Such amyloids have been associated with (but not necessarily as the cause of) more than 50 human diseases, including amyloidosis, and may play a role in some neurodegenerative diseases. Some of these diseases are mainly sporadic and only a few cases are familial. Others are only familial. Some result from medical treatment. Prions are an infectious form of amyloids that can act as a template to convert other non-infectious forms. Amyloids may also have normal biological functions; for example, in the formation of fimbriae in some genera of bacteria, transmission of epigenetic traits in fungi, as well as pigment deposition and hormone release in humans. Amyloids have been known to arise from many different proteins. These polypeptide chains generally form β-sheet structures that aggregate into long fibers; however, identical polypeptides can fold into multiple distinct amyloid conformations. The diversity of the conformations may have led to different forms of the prion diseases.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.